Autologous CD30.CAR-T in Combination With Nivolumab in cHL Patients After Failure of Frontline Therapy
Autologous CD30.CAR-T in Combination With Nivolumab in cHL Patients After Failure of Frontline Therapy
Active, not recruiting · NCT05352828 · Registry updated 2023-04-03Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Autologous CD30.CAR-T in Combination With Nivolumab in cHL Patients After Failure of Frontline Therapy | classic Hodgkin lymphoma | Active, not recruiting | Phase 1 | 2023-04-03 | NCT05352828 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Bristol-Myers Squibb | 422 |
| Tessa Therapeutics | 3 |
5 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Baylor College of Medicine | Houston | United States | 306 |
| City of Hope National Medical Center | Duarte | United States | 68 |
| MD Anderson Cancer Center | Houston | United States | 589 |
| UNC Lineberger Comprehensive Cancer Center | Chapel Hill | United States | 243 |
| University of Miami | Miami | United States | 327 |